BPC-157Check methods and identity
How a registered hamstring study plans to measure recovery
1 numbered sourceSource years 2026
Peptides are short chains of amino acids linked by peptide bonds. Some alter the activity of cells that respond to an injury. BPC-157 is an experimental 15-amino-acid peptide. A clinical trial registered in February 2026 proposes to study it in people with acute grade II hamstring strains confirmed by magnetic resonance imaging. The registry record describes how the investigators plan to measure healing and return to sport. [1]
The phase 2 study is designed to assign participants at random to BPC-157 or placebo. It is double-blind so that expectations about which treatment someone received are less likely to affect assessments or decisions about return to activity. The two primary measures are time to return to unrestricted sports participation and the change in injury volume on MRI. The registry also lists measures of strength and lower-limb function. [1]
The two primary outcomes capture separate parts of recovery. MRI can identify the extent of injured tissue using a defined reading procedure. Return to unrestricted participation requires a clinical assessment and performance on standardized tasks. Someone may have a smaller injury on a follow-up image and still need time to regain the strength or control needed for a particular sport. Conversely, functional progress can sometimes occur while an image still shows tissue changes. Measuring both helps determine whether any difference extends beyond the image. [1]
The registry listed the study as recruiting and showed no posted results when checked on November 8, 2026. Registration provides a record of the intended comparisons. Estimates of the magnitude of benefit, the uncertainty around it and the types of adverse events observed will depend on the actual study results. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
